Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B

Journal of Viral Hepatitis

Volumn 11, Issue 4, 2004, Pages 349-357

  Lin, S M ^a   Tai, D I ^a   Chien, R N ^a   Sheen, I S ^a   Chu, C M ^a   Liaw, Y F ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Lymphoblastoid interferon; Placebo; Recombinant interferon; Survival; Sustained response

Indexed keywords

LYMPHOBLAST INTERFERON; LYMPHOBLAST INTERFERON ALPHA; PLACEBO; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHRONIC HEPATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3242683269     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00512.x     Document Type: Article

References (37)

1. Collconi M, Buzzoni R, Bajetta E et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993; 72: 3196-3201.
2. Kardinal CG, Moertel CG, Wieand HS et al. Combined doxorubicin and alpha interferon therapy of advanced hepatocellular carcinoma. Cancer 1993; 71: 2187-2190.
3. Sachs E, Di Bisceglie AM, Dusheiko GM et al. Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: pilot study. Br J Cancer 1985; 52: 105-109.
4. Von Wussow P, Hartman F, Freund M, Poliwoda H, Deicher H. Leukocyte derived interferon-alpha in patients with antibodies to recombinant interferon-alpha2b. Lancet 1988; i: 822-823.
5. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145.
6. Roffi L, Mels GC, Antonelli G. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995; 21: 645-649.
7. Farrell GC, Bacon BR, Goldin RD, and the Clinical Advisory Group for Hepatitis C Comparative Study. Lymphoblastoid interferon alfa-nl improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Hepatology 1998; 27: 1121-1127.
8. Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 1997; 12 (Suppl.): 346S-353S.
9. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
10. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis. Hepatology 1994; 20: 1390-1398.
11. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
12. Oon CG. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylactics of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31 (Suppl.): 137S-142S.
13. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study. Cancer 1998; 82: 827-835.
14. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975.
15. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-2b treatment for hepatitis N antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-675.
16. Lau DTY, Everhart J, Kleiner DE et al. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667.
17. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-634.
18. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prenisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J Hepatol 1994; 20: 175-180.
19. Lok ASF, Wu PC, Lain CL et al. A controlled trial of interferon with or without prednisolone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
20. Chien RN, Sheen IS, Chu CM, Liaw YF. Beneficial effect of prednisolone priming and the need of maintenance interferon therapy in patients with chronic hepatitis B. J Hepatol 1993; 18 (Suppl.): 24S.
21. Liaw YF, Tai DY, Chu CM et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-267.
22. Liaw YF. Acute exacerbation and superinfection in patients with chronic viral hepatitis. J Formosan Med Assoc 1995; 94: 521-528.
23. Liaw YF, Pao CC, Chu CM, Sheen IS, Huang MJ. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis. Hepatology 1987; 7: 1-3.
24. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
25. Cox DR. Regression model and life tables. J R Stat Soc B 1972; 34: 187-220,
26. Saracco G, Mazzella G, Rosina F et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 336-341.
27. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000; 46: 562-568.
28. Krogsgaard K, Bindslev N, Christensen E et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patients data from 10 clinical controlled trials. J Hepatol 1994; 21: 646-655.
29. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-147.
30. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects on interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
31. Kuwana K, Ichida T, Kamimura T et al. Risk factors and the effect of interferon therapy in the development of hepatocellulr carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997; 12: 149-155.
32. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-1402.
33. Serfray L, Aumaitre H, Chazouillerres O et al. Determinants of outcome of compensated HCV-related cirrhosis. Hepatology 1998; 27: 1435-1440.
34. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Eng J Med 2002; 347: 168-174.
35. Carreno V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102-106.
36. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-1838.
37. Fattovich G, Giustina G, Realdi G, Schalm SW, Corrocher R, and the European Concerted Action of Viral Hepatitis (EUROHEP). Long-term outcome of HBeAg positive patients with compensated cirrhosis treated with interferon alpha. Hepatology 1997; 26: 1338-1342.